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Iron status is the result of the balance between the rate of erythropoiesis and the amount of the iron stores. Direct consequence
of an imbalance between the erythroid marrow iron requirements and the actual supply is a reduction of red cell hemoglobin
content, which causes hypochromic mature red cells and reticulocytes. The diagnosis of iron deficiency is particularly challenging
in patients with acute or chronic inflammatory conditions because most of the biochemical markers for iron metabolism (serum
ferritin and transferrin ) are affected by acute phase reaction. For these reasons, interest has been generated in the use of erythrocyte
and reticulocyte parameters, available on the modern hematology analyzers. Reported during blood analysis routinely performed
on the instrument, these parameters can assist in early detection of clinical conditions (iron deficiency, absolute, or functional;
ineffective erythropoiesis, including iron restricted or thalassemia), without additional cost. Technological progress has meant that
in recent years modern analyzers report new parameters that provide further information from the traditional count. Nevertheless
these new parameters are exclusive of each manufacturer, and they are patented. This is an update of these new laboratory test
biomarkers of hypochromia reported by different manufactures, their meaning, and clinical utility on daily practice.
1. Advances in Basic Science
The control of iron homeostasis acts at both the cellular and
the systemic level and involves a complex system of different
cell types, transporters, and signals. To maintain systemic
iron homeostasis, communication between cells that absorb
iron from the diet (duodenal enterocytes), consume iron
(mainly erythroid precursors), and store iron (hepatocytes
and tissue macrophages) must be tightly regulated [1].
In the last 10 years, understanding of the regulation of
iron homeostasis has changed substantially. A small peptide
hormone, hepcidin, emerged as the central regulator of
iron absorption, plasma iron levels, and iron distribution.
The hormone controls the iron homeostasis and acts by
inhibiting iron flows into plasma frommacrophages involved
in recycling of senescent erythrocytes, duodenal enterocytes
engaged in the absorption of dietary iron, and hepatocytes
that store iron [2].
The same factors that influence dietary iron absorption,
that is, iron stores, erythropoietic activity, hemoglobin, oxy-
gen content, and inflammation, also regulate the expression
of hepcidin by hepatocytes.
Hepcidin reduces the quantity of circulating iron by
limiting the egress of the metal from both intestinal and
macrophage cells and is the key for the regulation of systemic
iron homeostasis [3].
2. Iron Status
Absolute iron deficiency is defined as a decreased total iron
body content. Iron deficiency anemia (IDA) occurswhen iron
deficiency is sufficiently severe to diminish erythropoiesis
and cause the development of anemia.
Distinction between IDA and other entities in the
differential diagnosis of anemia, especially anemia that
accompanies infection, inflammation, and cancer, commonly
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termed anemia of chronic disease (ACD), to distinguishACD
from the combined state IDA/ACD is a daily challenge for
clinicians and laboratory professionals [4].
It has long been known that inflammation can mimic
some aspects of iron deficiency by impairing the utilization
of existing iron stores for red cell production and inducing
an iron-sequestration syndrome and low serum iron. The
molecular mechanisms that underlie the redistribution of
iron during inflammation center on the cytokine-stimulated
overproduction of hepcidin.
Functional iron deficiency describes a state where the
total iron content of the body is normal or even elevated, but
the iron is “locked away” and unavailable for the production
of red blood cells. Iron becomes limiting for erythropoiesis,
but generally the resulting anemia is not severe [2].
The laboratory diagnosis of absolute iron deficiency has
been based on low serum iron, low percent transferrin
saturation (TSAT), and low ferritin [5]. The limitations of
using transferrin saturation reflect those of serum iron, that
is, wide diurnal variation and low specificity. It is also reduced
in inflammatory disease [6, 7].
On the other hand, as ferritin is an acute phase reactant,
its serum levels may be elevated in the presence of chronic
inflammation, infection, malignancy, and liver disease, mak-
ing ferritin somewhat less than an ideal test for determining
iron deficiency [8].
Serum transferrin receptor (sTfR) is not affected by
inflammation [9] which would make sTfR a more reliable
test than serum ferritin when inflammation is present. sTfR
and the derived sTfR/log ferritin (ferritin index) are reliable
markers of iron deficiency in mixed situations [10].
A particular case of ACD is represented by anemia of
chronic kidney disease (CKD). Anemia is one of the most
characteristic manifestations of CKD. The most well-known
cause is inadequate production of erythropoietin, but there
are also other causes leading to impaired erythropoiesis
(reduced proliferative activity of erythroid precursors in bone
marrow, reduced survival of red cells, and decreased iron
availability), contributing to anemia [11, 12].
3. The Clinician’s Need for Reliable
Laboratory Tests
Recombinant human erythropoietin (rHuEpo) for the treat-
ment of CKD and patients with anemia related to cancer has
been available since 1989. However, rHuEpo therapy results
in functional iron deficiency due to insufficient iron stores for
the accelerated erythropoiesis [13].
Iron deficiency is the main cause of suboptimal response
to erythropoietin in dialysis patients. Maintenance iron sup-
plementation is required to successfully treat anemia. Long-
term orally administered iron therapy is limited by noncom-
pliance, gastrointestinal side effects, insufficient absorption,
and drug interaction; intravenous iron compounds are used
to treat dialysis patients who become iron deficient [14].
Monitoring erythropoietin treated patients’ iron status is
important to detect iron deficiency and avoid the adverse
effects of iron medication [15].
The most important question regarding anemia therapy
in these patients is which are the best parameters to assess the
iron available for erythropoiesis, and the need for predictors
and indicators of effectiveness has not abated [16, 17].
Interest has been generated in the use of erythrocyte and
reticulocyte new indices available on the modern analyzers
based on flow cytometry technology.
In 2004, European Best Practice Guidelines suggested
an hemoglobin (Hb) target of 110 g/L [18]; the assessment
of anemia in CKD patients should include the laboratory
measurement of the following parameters:
(i) Hb concentration, to assess the degree of anemia;
(ii) red blood cell indices (mean cell volume MCV, mean
cell hemoglobin MCH), to assess the type of anemia;
(iii) absolute reticulocyte count, to assess erythropoietic
activity;
(iv) serum ferritin concentration, to assess iron stores;
(v) functional iron available for erythropoiesis:
(a) percentage of hypochromic red cells (Siemens);
(b) transferrin saturation;
(c) reticulocyte hemoglobin content (Siemens);
(vi) plasma C-reactive protein, to assess inflammation.
Two parameters are exclusive of one-manufacturer’s
counters.
Direct consequence of an imbalance between the ery-
throid marrow iron requirements and the actual supply is
a reduction of red cell hemoglobin content, which causes
hypochromic mature red cells and reticulocytes.Themodern
hematological parameters contribute to the advanced study
of the anemia and depend on the technology employed;
the debate about other parameters with the same clinical
meaning and potential utility as reticulocyte hemoglobin
content and percentage of hypochromic red cells reported by
Siemens analyzers is open.
4. The Advance of Technology
The hemogram is one of the more required tests by the
clinicians, the analysis nowadays is totally automated, and the
correct interpretation of the results requires to reunite the
knowledge about the characteristics of the equipment and
the clinical meaning of the results. The suppliers contribute
innovations, providing new parameters that can help the
clinicians to make a diagnosis in a fast, cheap, and useful
manner [19].
The professionals of the clinical laboratory must obtain
the maximum yield of the new technologies obtaining as
much information as possible.
Automated blood cell counters have changed substan-
tially during the last 20 years. Technological progress has
meant that in recent yearsmodern analyzers, fully automated,
have been available. These analyzers report new parameters
that provide further information from the traditional count;
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Table 1: The new biomarkers of hypochromia now reported by the
analyzers of different manufacturers.
Parameter Abbreviation (unit) Company
Hypochromic RBC Hypo (%) Siemens
Reticulocyte Hb content CHr (pg) Siemens
Hypochromic RBC %HPO (%) Abbott
Reticulocyte Hb content MCHr (pg) Abbott
Hypochromic RBC Hypo He (%) Sysmex
Reticulocyte Hb equivalent Ret He (pg) Sysmex
Low Hb density LHD (%) Beckman Coulter
RBC: red blood cells; Hb: hemoglobin.
this information must be evaluated to prove the potential
clinical utility in different clinical situations.
Each company applies the technology in a different way
in the analyzers, and for this reason these new parameters are
exclusive of eachmanufacturer, and they are patented. Table 1
summarizes the RBC extended parameters now reported by
the different analyzers.
Flow cytometry provides information about individual
cell characteristics. This is in contrast to previous measure-
ments ofMCV,MCH, andMCHCwhich only calculatemean
values for the total red cell population.
Modern counters can provide information about the
reticulocyte counts but also about the characteristics of these
cells (size or Hb content), related to the quality of the ery-
thropoiesis, giving information of the current erythropoietic
activity of the bone marrow.
Reticulocytes are immature red blood cells with a life span
of only 1 to 2 days. When these are first released from the
bone marrow, measurement of their hemoglobin content or
volume can reflect the amount of iron immediately available
for erythropoiesis.
Red blood cells (RBCs) are continuously produced in
the bone marrow; when a state of iron deficiency proceeds
and the iron stores progressively decrease, mean cell volume
(MCV), mean cell hemoglobin (MCH), and red blood cell
count (RBC) tend to decline. In iron deficient erythropoiesis,
synthesis of Hb molecules is severely impaired leading to
the production of erythrocytes with low Hb concentration
(hypochromic cells). Because of their long-life span of
approximately 3 months, several cohorts of normochromic
and increasingly hypochromic red cells coexist in the periph-
eral blood leading to anisocytosis; red cell distribution width
(RDW) reflects the variation of size of the red cells.
Anisocytosis and anisochromia are related concepts but
not identical; RBCs undergo a rapid reduction in volume
and hemoglobin in the few days after release from the
bone marrow; in healthy individuals (and patients with
mild disease) the characteristics of the population can be
stable. But in clinical setting such as IDA the production
of reticulocytes appears to be counterbalanced by delayed
clearance of old cells, and the natural evolution of the red cells
is altered [20].
MCV is the mean of the volumes of all erythrocytes;
RDW refers to the variety of volumes present in the red cell
population, so the contribution of marginal-sized subsets to
the calculated mean value can be assessed.
This is not the case for Hb content. MCH is calculated
from red blood cell count and Hb and represents the average;
the percentage of RBC subsets can give complementary
information of the contribution of cell with extreme values
of Hb (hypochromic and hyperchromic cells) to the mean
values, reflecting the fluctuations of iron availability to the
erythron in the previous weeks.
The assessment of the erythrocyte subsets is an added
information can be useful, as it reflects the situation of the
whole of RBC.
5. Siemens (Siemens Healthcare Diagnostics,
Deerfield, IL, USA)
Applying flow cytometry technology, the detection of two
light-scatter signals allows the independent measurements of
cell-by-cell characteristics of volume and hemoglobin con-
centration; on the reticulocyte channel of ADVIA analyzers
immature red cells are stained based on their RNA content
using the stain Oxazine 750.
The hypochromic red cells (referred to as %Hypo) and
CHr (reticulocyte hemoglobin content) are reported by the
Siemens ADVIA 120 hematology analyzer (Siemens Medical
Solutions Diagnostics, Tarrytown, NY, USA). Reticulocyte
Hb content (CHr) and the percentage of hypochromic red
blood cells (%Hypo) reflect iron availability and are reliable
markers of functional iron deficiency [21, 22].
The measurement of CHr is a direct assessment of the
incorporation of iron into Hb and thus an estimate of the
recent functional availability of iron to the erythron; due to
the life span of the reticulocytes CHr is a sensitive indicator
of iron deficient erythropoiesis, cutoff 28-29 pg [23, 24].
rHuEpo is effective in stimulating production of red
blood cells, but without an adequate iron supply to bind to
heme, and the red blood cells will be hypochromic, low in Hb
concentration. Thus, in states of iron deficiency, a significant
percentage of red blood cells leaving the bone marrow will
have a low Hb concentration. By measuring the percentage
of RBCs with Hb concentration <280 g/L, iron deficiency
can be detected. Hypochromic red cells percentages have
been correlated with iron deficiency. %Hypo is reported by
Siemens Advia 120 hematology analyzer based on the optical
cell-by-cell hemoglobin measurement.
The measurement of %Hypo (defined as the percentage
of red blood cells with Hb concentration less than 280 g/L)
is a sensitive method for quantifying the hemoglobinization
of mature red cells. Because of the long circulating life span
of mature erythrocytes %Hypo values are related to iron
status in the last 2-3 months and have been recognised as
an indicator of iron deficiency [25–27]. %Hypo < 5% is
considered normal. Two different criteria, more specifically,
%Hypo > 5% and >10% have been used. %Hypo > 10%,
has been more commonly used for defining absolute iron
deficiency and functional iron deficiency [18].
CHr and %Hypo have been used as a diagnostic tool,
together with biochemical markers, to distinguish IDA from
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ACD, and are incorporated to the guidelines for the monitor-
ing of recombinant human erythropoietin rHuEpo therapy
[18, 28–31].These red blood cell and reticulocyte indices have
also been recognized as reliable markers of iron deficiency
on physiological conditions, where the demand for iron
increases (children, women at child bearing age, pregnancy)
[27, 32, 33].
The transition from the normal iron-replete state to
the development of iron deficiency anemia is a sequential
process: depletion of the storage iron compartment, followed
by its exhaustion and the consequent initiation of depletion of
the functional iron compartment. Normal Hb level does not
exclude lack of iron storage, because individuals with normal
body iron storesmust lose a large amount of body iron during
a long period before the Hb falls [34].
Nonanemic iron deficiency is sometimes termed “latent
iron deficiency” or “depleted iron stores.” Reticulocyte-
derived parameters can be useful in this context because they
give information regarding the actual iron supply and the
quality of the erythropoiesis within 2 days.
CHr could be a sensitive marker to detect early the
negative balance between body iron content and the demand
for erythropoiesis, before the mature cell indices or even Hb
move below the reference intervals, improving the diagnostic
algorithms [35–38].
The size of iron stores in blood donors can be also
evaluated with confidence by means of CHr [39–41].
6. Abbott (Abbott Diagnostics,
Santa Clara, CA, USA)
The flow-cytometric optical technology for RBC parameters
measurement was first made available by the Technicon
Company in their H∗ series of instruments, later followed
by the Advia hematology analyzers (Bayer Diagnostics,
presently Siemens Healthcare Diagnostics, Deerfield, IL,
USA). As a consequence, many of the data reported in the
literature have been generated using these analyzers. In 2010,
Abbott Diagnostics introduced extended RBC parameters on
the CELL-DYN Sapphire analyzer. The technology used in
this instrument is multiangle laser light scattering by single
cell, sphered RBC, and relies on the Mie theory, like what
the Advia analyzers do. Therefore, it was anticipated that
there would exist a very high level of agreement between the
extendedRBCparameters of both types of analyzer. Although
the parametersmeasured are identical, themanufacturers use
slightly different nomenclature (Table 1).
Mie theory describes the mathematics of light diffraction
by spherical objects; in this case the red cells are transformed
into isovolumetric spheres. When using monochromatic
(laser) light, diffraction is only a function of the size and the
refractive index of the object (related to its internal structure).
CELL-DYN Sapphire extended RBC parameters are pro-
duced collecting data of light in 3 different angles and in the
reticulocyte channel of the fluorescence signal.
Mathematical models in the software use these scatter
signals for calculating, for each individual cell, estimates of
cellular volume (𝑉) and cellular Hb concentration (CHC);
these parameters can be specifically calculated for reticulo-
cytes, too mean cellular volume of reticulocytes (MCVr) and
mean cellular Hb content of reticulocytes (MCHr).
Thewhole RBCpopulation can be classify considering the
Hb concentration:
%HPO is the percentage of hypochromic RBC with
CHC < 280 g/L,
%HPR the percentage the percentage of hyper-
chromic RBC, CHC > 410 g/L.
It has been published the new extended RBC parameters
as measured on CELL-DYN Sapphire show a high degree of
correlation with those of the Advia analyzers, although the
absolute values may differ [42, 43]. This renders it necessary
to establish instrument-specific reference ranges and clinical
decision values [44, 45].
The reference intervals for %HPO and MCHr have been
established, 0–4.8% and 28.5–34.5 pg, respectively [44], and
the median in patients with no anemia (2.7% for %HPO and
29.9 pg for MCHr), are already published [43].
Although the numerical values do differ from the Advia
parameters because of differences in technology, their clinical
utility seems to be rather comparable [43].
7. Sysmex (Sysmex Corporation, Kobe, Japan)
Sysmex XE analyzers (Sysmex Corporation, Kobe, Japan)
employ flow cytometry technology. In the reticulocyte chan-
nel blood cells are stained by a polymethine dye, specific
for RNA/DNA. A bi-dimensional distribution of forward
scattered light and fluorescence is presented as a scattergram,
indicating mature red cells and reticulocytes. Forward scatter
correlates with erythrocyte and reticulocyte Hb content, the
so-called RBC Hb equivalent (RBC He), reticulocyte Hb
equivalent (Ret He).
Measurements of Ret He provide useful information
in diagnosing anemia, iron-restricted erythropoiesis, and
functional iron deficiency and response to iron therapy
during rHuEpo therapy [46–49]; Ret He, generated by all
SysmexXE analyzers (SysmexCorporation, Kobe, Japan), has
been recognised as a direct assessment of the incorporation
of iron into erythrocyte Hb and a direct estimate of the
recent functional availability of iron, thus provides the same
information as CHr [50–52]. Twenty-nine pg is the cutoff
value that defines deficient erythropoiesis. Ret He correlates
with CHr with the same clinical meaning [53–55].
The role inflammation impairing the utilization of exist-
ing iron stores has been explained previously; recent articles
focus on critically ill patients and the attempts to introduce
Ret He in the transfusion area improving the management
of anemic patients in critical conditions [56, 57]. The iron
sequestration in the macrophages could be an evolutionary
mechanism of defense against determined pathogens of high
virulence [1]; impairment of reticulocyte Hb content can be
considered as a consequence of infection and activation of
mechanisms of immunity [58].
Derived from RBC Hb equivalent (RBC He), the Sysmex
XE 5000 analyzer reports the percentages of hypochromic red
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cells; %HypoHe indicates the percentage of hypochromic red
cells with an Hb content less than 17 pg. Reference intervals
are already published [59].
Recent studies confirm the clinical reliability of %Hypo
He as marker of iron availability [60] and the assessment
of functional iron deficiency in hemodialysis patients [61];
2.7% is the cutoff value which defines iron deficiency in those
patients [62].
8. Beckman Coulter (Beckman Coulter Inc.
Miami, FL, USA)
Beckman Coulter (Beckman Coulter Inc. Miami, FL, USA)
applies the Volume Conductivity Scatter technology to this
field and new parameters are now available on the LH series
analyzers.
Low hemoglobin density (LHD%) derives from the tradi-
tional mean cell hemoglobin concentration (MCHC), using
the following mathematical sigmoid transformation:




MCHC is an inclusive measure of both the availability of
iron over the preceding 90–120 days and of the proper
introduction of iron into intracellular Hb. In the same way
LHD% is related to iron availability and the Hb content of
the mature red cells.
In this equation defining LHD%, in addition to the
standard sigmoid function, a square root is applied to further
enhance numerical resolution in the lower end region, to
improve the differentiation between the normal and the
abnormal among the blood samples having relatively low
values of LHD%.
The reference range and the values of LHD% in normal
population have been established, 1.0–4.0%, and the correla-
tionwith%Hypo values and its clinical usefulness in the study
of iron status have been assessed [63].
LHD% is a reliable parameter for the detection of iron
deficiency in patients with anemia in the presence of inflam-
mation [64], recognizes subsets of patients, and therefore
improves the diagnosis andmanagement of anemia; LHD% >
6.0% suggests iron deficiency [65, 66].
9. Summary
The official National Institutes of Health definition of a
biomarker is “a characteristic that is objectively measured
and evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic response to a ther-
apeutic intervention” [67]. More generally, a biomarker is
a laboratory measurement that can be used to measure the
progress of disease or the effects of treatment, as the newRBC
extended parameters can do and is proved in the published
studies selected in the reference section.
The percentage of hypochromic erythrocytes and the
reticulocyte Hb content, reported by the modern analyzers,
expand information at a cellular level:
(1) provide Hb content information on red cells;
(2) monitor changes in Hb incorporation into erythron;
(3) are more sensitive than indirect Biochemical mea-
surements.
Operational Efficiency:
(i) rapid and automated;
(ii) rapid information to Clinicians of iron status;
(iii) faster response to changes from therapy;
(iv) financial justification.
Aids clinicians in
(i) assessing true status of iron;
(ii) detect functional iron deficiency, patients who
can benefit from therapy;
(iii) differential diagnosis.
10. Conclusions
Several findings in the field of iron metabolism and erythro-
poiesis are modifying the traditional concepts on anemia.
These findings point out the need for reliable diagnostic tests
that are able to allow the better evaluation of the causes
underlying apparently similar clinical conditions, implying a
stronger collaboration between laboratory professionals and
clinicians in order to optimize patient treatment.
Anemia is defined as a decrease concentration of Hb in
the blood, cutoff depending on age and gender, but isolated
Hb measurement has both low specificity and low sensitivity.
The latter can be improved by including measures of iron-
deficient erythropoiesis.
The biomarkers of hypochromia provide information
about the iron supply and are reliable markers of iron
restricted erythropoiesis in complex clinical situations.
An appropriate combination of laboratory tests gives
evidence of iron depletion, reflects iron restricted red cells
production, and so will help to establish a correct assessment
of the iron status and thus the appropriate treatment.
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